Last reviewed · How we verify

NCT06946329: WATERinMOTION

WATERinMOTION Aquatic Therapy in Obese Men With Knee Osteoarthritis

ENROLLING BY INVITATION NA Last updated 27 April 2025
What this trial tests

NA trial testing Aquatic Exercise in Osteoarthritis in 100 participants. Enrolling by invitation.

Timeline
1 March 2024
Primary endpoint
30 September 2024
1 May 2025

Quick facts

Lead sponsorUniversity of Sistan and Baluchestan
PhaseNA
StatusENROLLING BY INVITATION
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment100
Start date1 March 2024
Primary completion30 September 2024
Estimated completion1 May 2025
Sites1 location across Iran

Drugs / interventions tested

Conditions studied

Sponsor

University of Sistan and Baluchestan

Who can join

Adults 45 to 65, male only, with Osteoarthritis or Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This RCT evaluates whether WATERinMOTION aquatic therapy improves pain, function, and quality of life more effectively than land-based exercise in obese men with knee osteoarthritis (OA). We will assess clinical outcomes (WOMAC), serum biomarkers (COMP, IL-6), and real-world activity (accelerometry) at baseline, 8 weeks, and 6 months.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Aquatic Exercise

Trials testing the same drug.

Other recruiting trials for Osteoarthritis

Currently open trials in the same condition.

Other University of Sistan and Baluchestan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06946329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing